PCR Journal Club

This study provides the longest available follow-up for first-generation bioresorbable vascular scaffolds and fails to demonstrate any late clinical advantage after complete scaffold resorption.

The 3-year follow-up of the REC-CAGEFREE I trial demonstrated that a DCB-based strategy with rescue stenting was associated with a significantly higher rate of DOCE compared with contemporary DES implantation in patients with de novo, non-complex coronary artery disease.

This individual patient data analysis of the three largest RCTs evaluating IVUS-guided stent optimisation showed that an MSA > 5.5 mm2 was associated with reduced TVF at one year. 

Which ballooning technique is best after main vessel stenting in bifurcation PCI? This two-part study compares two key approaches: PKP (POT, kissing balloon inflation, final POT) and PSP (POT, isolated side branch dilation, final POT) to determine the optimal strategy.

At two-year follow-up, the use of sirolimus-eluting cobalt-chromium DynamX Drug Eluting Coronary Bioadaptor System (Elixir Medical Corporation) resulted in fewer target lesion failure (TLF) compared with the Resolute Onyx contemporary drug-eluting stent.

Due to a lack of randomised evidence, this randomised controlled trial (RCT) aimed to compare the safety and efficacy of IVL and ELCA with RA in treating heavily calcified coronary lesions before drug-eluting stent implantation.

The present study compares a novel sirolimus-coated balloon with a clinically proven paclitaxel-coated balloon for the treatment of de novo coronary lesions, demonstrating non-inferiority in terms of angiographic late lumen loss at 6 months.

The aim of this pre-specified analysis of the ILUMIEN IV trial was to assess the relationship between post-PCI OCT parameters of suboptimal stent implantation and clinical outcomes.

This trial found that, in ACS patients undergoing PCI, DP-DES and BP-DES had similar patient-oriented outcomes at three years, but BP-DES had higher device-oriented composite outcomes, mainly due to increased TLR risk.

The trial aimed to establish the non-inferiority of QCA-guided PCI compared to IVUS-guided PCI with respect to the primary endpoint of TLF at 12 months, defined as a composite of cardiac death, target vessel MI, or ischemia-driven target lesion revascularization.